Mortality of patients excluded from the Danish Verapamil Infarction Trail II. The DAVIT-II Study Group.:

J K Madsen; J F Hansen

Mortality of patients excluded from the Danish Verapamil Infarction Trail II. The DAVIT-II Study Group.

J K Madsen
, J F Hansen

Department of Cardiology

Abstract

The 18 month mortality rate in 2180 patients excluded from the Danish Verapamil Infarction Trail II (DAVIT II) was 25.6%. In non-consenters (n = 368) this was 15.0% compared with 13.85 in 897 placebo-treated patients (hazard ratio 1.09 [P = 0.60] when adjusting for sex and age). The increased mortality rate in excluded patients is attributed to heart failure (45.8%) and other severe diseases (38.9%).

Translated title of the contribution	Mortality of patients excluded from the Danish Verapamil Infarction Trail II. The DAVIT-II Study Group.
Original language	English
Journal	European Heart Journal
Volume	14
Issue number	3
Pages (from-to)	377-379
Number of pages	3
ISSN	0195-668X
Publication status	Published - 1993

Access to Document

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8096180&query_hl=112

Cite this

@article{2f1bafacd6de441fb1971fbc73fbf5ff,

title = "Mortality of patients excluded from the Danish Verapamil Infarction Trail II. The DAVIT-II Study Group.",

abstract = "The 18 month mortality rate in 2180 patients excluded from the Danish Verapamil Infarction Trail II (DAVIT II) was 25.6\%. In non-consenters (n = 368) this was 15.0\% compared with 13.85 in 897 placebo-treated patients (hazard ratio 1.09 [P = 0.60] when adjusting for sex and age). The increased mortality rate in excluded patients is attributed to heart failure (45.8\%) and other severe diseases (38.9\%).",

author = "Madsen, \{J K\} and Hansen, \{J F\}",

year = "1993",

language = "English",

volume = "14",

pages = "377--379",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Mortality of patients excluded from the Danish Verapamil Infarction Trail II. The DAVIT-II Study Group.

AU - Madsen, J K

AU - Hansen, J F

PY - 1993

Y1 - 1993

N2 - The 18 month mortality rate in 2180 patients excluded from the Danish Verapamil Infarction Trail II (DAVIT II) was 25.6%. In non-consenters (n = 368) this was 15.0% compared with 13.85 in 897 placebo-treated patients (hazard ratio 1.09 [P = 0.60] when adjusting for sex and age). The increased mortality rate in excluded patients is attributed to heart failure (45.8%) and other severe diseases (38.9%).

AB - The 18 month mortality rate in 2180 patients excluded from the Danish Verapamil Infarction Trail II (DAVIT II) was 25.6%. In non-consenters (n = 368) this was 15.0% compared with 13.85 in 897 placebo-treated patients (hazard ratio 1.09 [P = 0.60] when adjusting for sex and age). The increased mortality rate in excluded patients is attributed to heart failure (45.8%) and other severe diseases (38.9%).

M3 - Journal article

SN - 0195-668X

VL - 14

SP - 377

EP - 379

JO - European Heart Journal

JF - European Heart Journal

IS - 3

ER -